Global Antiprotozoal drugs Market

Antiprotozoal drugs Comprehensive Study by Type (Chloroquine, Pyrimethamine, Mefloquine, Hydroxychloroquine, Metronidazole, Atovaquone, Others), Application (Healthcare and Hospital, Others), Form (Liquid, Tablet, Injectable form), Distribution (Online Pharmacy, Offline Pharmacy) Players and Region - Global Market Outlook to 2028

Antiprotozoal drugs Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Antiprotozoal drugs Market Scope?
Antiprotozoal drugs are the category of the drug used to treat infection caused due to protozoa, type of parasite. Protozoal infection spread majorly in Africa and South-East Asia. These are classified into antimalarial drugs and miscellaneous antiprotozoal. Increasing prevalence of protozoan infections give drive to the antiprotozoal drugs market

Market Growth Drivers:
Increasing prevalence of protozoan infections, Favourable government support to treat malaria and Availability of generic version at a cheaper price

Challenges:
High Cost of Manufacturing

Restraints:
Side Effects associated with the drugs

Opportunities:
Ongoing research and development for Drug Development to Protozoan Diseases

The Antiprotozoal drugs market study is being classified by Type (chloroquine, pyrimethamine, mefloquine, hydroxychloroquine, metronidazole, atovaquone and Others), by Application and major geographies with country level break-up.

The market is densely competitive due to presence of vast number of companies offering various products Analysts at AMA predicts that Players from Players concentration is mainly in Europe will contribute to the maximum growth of Global Antiprotozoal drugs market throughout the predicted period.

Enzon Pharmaceuticals (United States), Sanofi (France), Pfizer, Inc. (United States), Sun Pharmaceutical Industries Ltd. (India), GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), Ipca Laboratories Ltd. (India), Merck KGaA (Germany) and F. Hoffmann La-Roche Ltd. (Switzerland) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Paladin Therapeutics, Inc. (Canada), Sequus Pharmaceuticals (United States) and Lifecare Innovation (India).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Antiprotozoal drugs market by Type, Application and Region.

On the basis of geography, the market of Antiprotozoal drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

In 2018, Lupin, an India based pharmaceutical giant announced launch of Atovaquone Oral Suspension, 750 mg/5 mL is the generic equivalent of Glaxosmithkline LLC’s Mepron oral suspension for Pneumocystis jirovecii pneuomonia (PCP) for young and adult patients
In July 2018, the GSK received United States Food and Drug Administration (FDA) approval for the single-dose Krintafel (tafenoquine) for the radical cure (of the Plasmodium vivax (P. vivax) malaria

Key Target Audience
Pharmaceutical Companies, Government and Research Institutes

Antiprotozoal drugs Market Study: Important Years
AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Major Highlights of Market Study

Demand Determinants: Identifying top-notch application and business segments that seek high growth potentials in Antiprotozoal drugs Market.

Key Strategic Developments: To target untapped regions more aggressively by focusing on product/service developments, innovation and R & D, new launches, Merger & acquisitions, JVs & partnerships.

Forces & Market Dynamics: Growth drivers, restraints & opportunities available in Antiprotozoal drugs industry is examined with reference relevant market sectors and sub-sectors.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also includes significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets, To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • chloroquine
  • pyrimethamine
  • mefloquine
  • hydroxychloroquine
  • metronidazole
  • atovaquone
  • Others
By Application
  • Healthcare and Hospital
  • Others
By Form
  • Liquid
  • Tablet
  • Injectable form

By Distribution
  • Online Pharmacy
  • Offline Pharmacy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing prevalence of protozoan infections
      • 3.2.2. Favourable government support to treat malaria
      • 3.2.3. Availability of generic version at a cheaper price
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Manufacturing
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antiprotozoal drugs, by Type, Application, Form, Distribution and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Antiprotozoal drugs (Value)
      • 5.2.1. Global Antiprotozoal drugs by: Type (Value)
        • 5.2.1.1. Chloroquine
        • 5.2.1.2. Pyrimethamine
        • 5.2.1.3. Mefloquine
        • 5.2.1.4. Hydroxychloroquine
        • 5.2.1.5. Metronidazole
        • 5.2.1.6. Atovaquone
        • 5.2.1.7. Others
      • 5.2.2. Global Antiprotozoal drugs by: Application (Value)
        • 5.2.2.1. Healthcare and Hospital
        • 5.2.2.2. Others
      • 5.2.3. Global Antiprotozoal drugs by: Form (Value)
        • 5.2.3.1. Liquid
        • 5.2.3.2. Tablet
        • 5.2.3.3. Injectable form
      • 5.2.4. Global Antiprotozoal drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Antiprotozoal drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Enzon Pharmaceuticals (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Ipca Laboratories Ltd. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck KGaA (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. F. Hoffmann La-Roche Ltd. (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Antiprotozoal drugs Sale, by Type, Application, Form, Distribution and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Antiprotozoal drugs (Value)
      • 7.2.1. Global Antiprotozoal drugs by: Type (Value)
        • 7.2.1.1. Chloroquine
        • 7.2.1.2. Pyrimethamine
        • 7.2.1.3. Mefloquine
        • 7.2.1.4. Hydroxychloroquine
        • 7.2.1.5. Metronidazole
        • 7.2.1.6. Atovaquone
        • 7.2.1.7. Others
      • 7.2.2. Global Antiprotozoal drugs by: Application (Value)
        • 7.2.2.1. Healthcare and Hospital
        • 7.2.2.2. Others
      • 7.2.3. Global Antiprotozoal drugs by: Form (Value)
        • 7.2.3.1. Liquid
        • 7.2.3.2. Tablet
        • 7.2.3.3. Injectable form
      • 7.2.4. Global Antiprotozoal drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antiprotozoal drugs: by Type(USD Million)
  • Table 2. Antiprotozoal drugs Chloroquine , by Region USD Million (2017-2022)
  • Table 3. Antiprotozoal drugs Pyrimethamine , by Region USD Million (2017-2022)
  • Table 4. Antiprotozoal drugs Mefloquine , by Region USD Million (2017-2022)
  • Table 5. Antiprotozoal drugs Hydroxychloroquine , by Region USD Million (2017-2022)
  • Table 6. Antiprotozoal drugs Metronidazole , by Region USD Million (2017-2022)
  • Table 7. Antiprotozoal drugs Atovaquone , by Region USD Million (2017-2022)
  • Table 8. Antiprotozoal drugs Others , by Region USD Million (2017-2022)
  • Table 9. Antiprotozoal drugs: by Application(USD Million)
  • Table 10. Antiprotozoal drugs Healthcare and Hospital , by Region USD Million (2017-2022)
  • Table 11. Antiprotozoal drugs Others , by Region USD Million (2017-2022)
  • Table 12. Antiprotozoal drugs: by Form(USD Million)
  • Table 13. Antiprotozoal drugs Liquid , by Region USD Million (2017-2022)
  • Table 14. Antiprotozoal drugs Tablet , by Region USD Million (2017-2022)
  • Table 15. Antiprotozoal drugs Injectable form , by Region USD Million (2017-2022)
  • Table 16. South America Antiprotozoal drugs, by Country USD Million (2017-2022)
  • Table 17. South America Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 18. South America Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 19. South America Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 20. South America Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 21. Brazil Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 22. Brazil Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 23. Brazil Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 24. Brazil Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 25. Argentina Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 26. Argentina Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 27. Argentina Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 28. Argentina Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 29. Rest of South America Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 30. Rest of South America Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 31. Rest of South America Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 32. Rest of South America Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 33. Asia Pacific Antiprotozoal drugs, by Country USD Million (2017-2022)
  • Table 34. Asia Pacific Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 35. Asia Pacific Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 36. Asia Pacific Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 37. Asia Pacific Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 38. China Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 39. China Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 40. China Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 41. China Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 42. Japan Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 43. Japan Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 44. Japan Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 45. Japan Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 46. India Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 47. India Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 48. India Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 49. India Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 50. South Korea Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 51. South Korea Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 52. South Korea Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 53. South Korea Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 54. Taiwan Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 55. Taiwan Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 56. Taiwan Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 57. Taiwan Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 58. Australia Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 59. Australia Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 60. Australia Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 61. Australia Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 62. Rest of Asia-Pacific Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 63. Rest of Asia-Pacific Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 66. Europe Antiprotozoal drugs, by Country USD Million (2017-2022)
  • Table 67. Europe Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 68. Europe Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 69. Europe Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 70. Europe Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 71. Germany Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 72. Germany Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 73. Germany Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 74. Germany Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 75. France Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 76. France Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 77. France Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 78. France Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 79. Italy Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 80. Italy Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 81. Italy Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 82. Italy Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 83. United Kingdom Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 84. United Kingdom Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 85. United Kingdom Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 86. United Kingdom Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 87. Netherlands Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 88. Netherlands Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 89. Netherlands Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 90. Netherlands Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 91. Rest of Europe Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 92. Rest of Europe Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 93. Rest of Europe Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 94. Rest of Europe Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 95. MEA Antiprotozoal drugs, by Country USD Million (2017-2022)
  • Table 96. MEA Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 97. MEA Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 98. MEA Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 99. MEA Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 100. Middle East Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 101. Middle East Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 102. Middle East Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 103. Middle East Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 104. Africa Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 105. Africa Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 106. Africa Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 107. Africa Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 108. North America Antiprotozoal drugs, by Country USD Million (2017-2022)
  • Table 109. North America Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 110. North America Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 111. North America Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 112. North America Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 113. United States Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 114. United States Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 115. United States Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 116. United States Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 117. Canada Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 118. Canada Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 119. Canada Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 120. Canada Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 121. Mexico Antiprotozoal drugs, by Type USD Million (2017-2022)
  • Table 122. Mexico Antiprotozoal drugs, by Application USD Million (2017-2022)
  • Table 123. Mexico Antiprotozoal drugs, by Form USD Million (2017-2022)
  • Table 124. Mexico Antiprotozoal drugs, by Distribution USD Million (2017-2022)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Antiprotozoal drugs: by Type(USD Million)
  • Table 135. Antiprotozoal drugs Chloroquine , by Region USD Million (2023-2028)
  • Table 136. Antiprotozoal drugs Pyrimethamine , by Region USD Million (2023-2028)
  • Table 137. Antiprotozoal drugs Mefloquine , by Region USD Million (2023-2028)
  • Table 138. Antiprotozoal drugs Hydroxychloroquine , by Region USD Million (2023-2028)
  • Table 139. Antiprotozoal drugs Metronidazole , by Region USD Million (2023-2028)
  • Table 140. Antiprotozoal drugs Atovaquone , by Region USD Million (2023-2028)
  • Table 141. Antiprotozoal drugs Others , by Region USD Million (2023-2028)
  • Table 142. Antiprotozoal drugs: by Application(USD Million)
  • Table 143. Antiprotozoal drugs Healthcare and Hospital , by Region USD Million (2023-2028)
  • Table 144. Antiprotozoal drugs Others , by Region USD Million (2023-2028)
  • Table 145. Antiprotozoal drugs: by Form(USD Million)
  • Table 146. Antiprotozoal drugs Liquid , by Region USD Million (2023-2028)
  • Table 147. Antiprotozoal drugs Tablet , by Region USD Million (2023-2028)
  • Table 148. Antiprotozoal drugs Injectable form , by Region USD Million (2023-2028)
  • Table 149. South America Antiprotozoal drugs, by Country USD Million (2023-2028)
  • Table 150. South America Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 151. South America Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 152. South America Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 153. South America Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 154. Brazil Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 155. Brazil Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 156. Brazil Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 157. Brazil Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 158. Argentina Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 159. Argentina Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 160. Argentina Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 161. Argentina Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 162. Rest of South America Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 163. Rest of South America Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 164. Rest of South America Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 165. Rest of South America Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 166. Asia Pacific Antiprotozoal drugs, by Country USD Million (2023-2028)
  • Table 167. Asia Pacific Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 168. Asia Pacific Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 169. Asia Pacific Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 170. Asia Pacific Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 171. China Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 172. China Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 173. China Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 174. China Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 175. Japan Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 176. Japan Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 177. Japan Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 178. Japan Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 179. India Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 180. India Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 181. India Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 182. India Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 183. South Korea Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 184. South Korea Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 185. South Korea Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 186. South Korea Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 187. Taiwan Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 188. Taiwan Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 189. Taiwan Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 190. Taiwan Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 191. Australia Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 192. Australia Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 193. Australia Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 194. Australia Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 195. Rest of Asia-Pacific Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 196. Rest of Asia-Pacific Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 197. Rest of Asia-Pacific Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 198. Rest of Asia-Pacific Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 199. Europe Antiprotozoal drugs, by Country USD Million (2023-2028)
  • Table 200. Europe Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 201. Europe Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 202. Europe Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 203. Europe Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 204. Germany Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 205. Germany Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 206. Germany Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 207. Germany Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 208. France Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 209. France Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 210. France Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 211. France Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 212. Italy Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 213. Italy Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 214. Italy Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 215. Italy Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 216. United Kingdom Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 217. United Kingdom Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 218. United Kingdom Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 219. United Kingdom Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 220. Netherlands Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 221. Netherlands Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 222. Netherlands Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 223. Netherlands Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 224. Rest of Europe Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 225. Rest of Europe Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 226. Rest of Europe Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 227. Rest of Europe Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 228. MEA Antiprotozoal drugs, by Country USD Million (2023-2028)
  • Table 229. MEA Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 230. MEA Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 231. MEA Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 232. MEA Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 233. Middle East Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 234. Middle East Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 235. Middle East Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 236. Middle East Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 237. Africa Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 238. Africa Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 239. Africa Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 240. Africa Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 241. North America Antiprotozoal drugs, by Country USD Million (2023-2028)
  • Table 242. North America Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 243. North America Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 244. North America Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 245. North America Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 246. United States Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 247. United States Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 248. United States Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 249. United States Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 250. Canada Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 251. Canada Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 252. Canada Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 253. Canada Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 254. Mexico Antiprotozoal drugs, by Type USD Million (2023-2028)
  • Table 255. Mexico Antiprotozoal drugs, by Application USD Million (2023-2028)
  • Table 256. Mexico Antiprotozoal drugs, by Form USD Million (2023-2028)
  • Table 257. Mexico Antiprotozoal drugs, by Distribution USD Million (2023-2028)
  • Table 258. Research Programs/Design for This Report
  • Table 259. Key Data Information from Secondary Sources
  • Table 260. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antiprotozoal drugs: by Type USD Million (2017-2022)
  • Figure 5. Global Antiprotozoal drugs: by Application USD Million (2017-2022)
  • Figure 6. Global Antiprotozoal drugs: by Form USD Million (2017-2022)
  • Figure 7. South America Antiprotozoal drugs Share (%), by Country
  • Figure 8. Asia Pacific Antiprotozoal drugs Share (%), by Country
  • Figure 9. Europe Antiprotozoal drugs Share (%), by Country
  • Figure 10. MEA Antiprotozoal drugs Share (%), by Country
  • Figure 11. North America Antiprotozoal drugs Share (%), by Country
  • Figure 12. Global Antiprotozoal drugs share by Players 2022 (%)
  • Figure 13. Global Antiprotozoal drugs share by Players (Top 3) 2022(%)
  • Figure 14. Global Antiprotozoal drugs share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Enzon Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 17. Enzon Pharmaceuticals (United States) Revenue: by Geography 2022
  • Figure 18. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 19. Sanofi (France) Revenue: by Geography 2022
  • Figure 20. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pfizer, Inc. (United States) Revenue: by Geography 2022
  • Figure 22. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 23. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2022
  • Figure 24. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2022
  • Figure 26. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 28. Ipca Laboratories Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 29. Ipca Laboratories Ltd. (India) Revenue: by Geography 2022
  • Figure 30. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Merck KGaA (Germany) Revenue: by Geography 2022
  • Figure 32. F. Hoffmann La-Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. F. Hoffmann La-Roche Ltd. (Switzerland) Revenue: by Geography 2022
  • Figure 34. Global Antiprotozoal drugs: by Type USD Million (2023-2028)
  • Figure 35. Global Antiprotozoal drugs: by Application USD Million (2023-2028)
  • Figure 36. Global Antiprotozoal drugs: by Form USD Million (2023-2028)
  • Figure 37. South America Antiprotozoal drugs Share (%), by Country
  • Figure 38. Asia Pacific Antiprotozoal drugs Share (%), by Country
  • Figure 39. Europe Antiprotozoal drugs Share (%), by Country
  • Figure 40. MEA Antiprotozoal drugs Share (%), by Country
  • Figure 41. North America Antiprotozoal drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Enzon Pharmaceuticals (United States)
  • Sanofi (France)
  • Pfizer, Inc. (United States)
  • Sun Pharmaceutical Industries Ltd. (India)
  • GlaxoSmithKline plc (United Kingdom)
  • Novartis AG (Switzerland)
  • Ipca Laboratories Ltd. (India)
  • Merck KGaA (Germany)
  • F. Hoffmann La-Roche Ltd. (Switzerland)
Additional players considered in the study are as follows:
Paladin Therapeutics, Inc. (Canada) , Sequus Pharmaceuticals (United States) , Lifecare Innovation (India)
Select User Access Type

Key Highlights of Report


Jun 2023 214 Pages 70 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Antiprotozoal drugs Market Quantitative research analysis
Global Antiprotozoal drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The prominent players of Global Antiprotozoal drugs market are Enzon Pharmaceuticals (United States), Sanofi (France), Pfizer, Inc. (United States), Sun Pharmaceutical Industries Ltd. (India), GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), Ipca Laboratories Ltd. (India), Merck KGaA (Germany) and F. Hoffmann La-Roche Ltd. (Switzerland).
In this highly competitive & fast evolving Antiprotozoal drugs industry, the top strategic priorities would remain consistent like innovation, R&D, and M&A.
Healthcare and Hospital and Others are the potential customers of Antiprotozoal drugs industry.

Know More About Global Antiprotozoal drugs Market Report?

Have a Query? Click Here

Other Related Reports

Pediatrics Respiratory Drugs Comprehensive Study by Disease Type (Asthma, Cystic Fibrosis, Bronchiolitis, Pneumonia, Tuberculosis, Others), Distribution Channel (Hospitals & Clinics, Retail Pharmacie...
$ 3750
Suplatast Tosilate Comprehensive Study by Type (Antiasthmatic agent, Antiallergic agent), Application (Hospitals, Cancer Research Centers, Clinics), Modility (Research, Commercialized), Distribution ...
$ 3350
Postpartum Bleeding Drug Comprehensive Study by Type (Oxytocin, Methergine, Hemabate, Misoprostol, Carboprost, Tranexamic acid, Others), End-user (Hospitals, Maternity Clinics, Out-of-hospital emerge...
$ 3450
Amitriptyline Comprehensive Study by Application (Depression, Migraine, Insomnia, Rheumatic diseases), Form (Tablet, Liquid), Distribution (Online Pharmacy, Hospital Pharmacy, Generic Drug Store), D...
$ 3350
Hemorrhoids Ointment Comprehensive Study by Type (Paste, Gelatinous, Others), Application (Internal Hemorrhoids, External Hemorrhoids, Mixed Hemorrhoids), Distribution Channel (Retail pharmacies, Hos...
$ 3350
Primidone Comprehensive Study by Application (Epilepsy, Essential Tremor, Psychiatric Disorders), Patient Type (Adult, Pediatric), Distribution Channel (Hospitals & Clinics, Retail Pharmacies, Online...
$ 3450